Maravai LifeSciences Holdings

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The Protein Detection segment is engaged in manufacturing and selling labeling and visual detection reagents to scientific research customers for their tissue-based protein detection and characterization needs. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Maravai LifeSciences reports record earnings, eyes sustainable growth strategies

Maravai LifeSciences delivered strong financial performance in Q4 2022 and full year 2022, with record revenue and robust margins, supported by strategic acquisitions and diversified revenue streams.
While facing challenges such as geopolitical risks and margin fluctuations, the company is well-positioned to capitalize on growth opportunities in the cell and gene therapy market, driven by customer-centric strategies and market stability.
By focusing on sustainable growth, ESG initiatives, and customer adaptation, Maravai aims to maintain its competitive edge and drive long-term value creation for shareholders and stakeholders.
The company's commitment to innovation, market expansion, and operational efficiency underscores its resilience and potential for continued success in the evolving biotechnology landscape.

Maravai LifeSciences reports solid Q1 results amidst market challenges

Maravai LifeSciences delivered strong financial performance in Q1 2023, driven by core business strength and innovation.
While facing challenges in the biotech market and revenue decline, the company is strategically positioned for growth.
Opportunities lie in customer adoption, inorganic growth, and recovery in key markets like China.

Maravai LifeSciences adjusts revenue guidance amidst industry demand weakness

Maravai LifeSciences faces near-term challenges with revenue guidance adjustments but maintains confidence in long-term growth prospects. The company is strategically positioned in mRNA and nucleic acid chemistry, focusing on innovation and cost management strategies to drive future success.

Maravai LifeSciences reports strong Q3 earnings, eyes biotech market growth

Maravai LifeSciences Holdings reported solid Q3 performance, focusing on cost reductions and strategic investments. Despite challenges in customer conversations and limited visibility for 2024, the company remains optimistic about growth opportunities in key markets.

Maravai LifeSciences posts robust Q4 results and targets diversified growth

Maravai LifeSciences delivered strong Q4 results and expects continued growth in 2024 with a more diversified customer base.
The company's focus on innovation, efficiency, and customer commitment positions it well for future success.
While facing revenue challenges in Q1, Maravai's performance in Biologic Safety Testing segment provides stability.
Margin expansion tied to top-line growth and CleanCap technology adoption present promising opportunities for the company.

Maravai LifeSciences reports solid Q1 performance amidst growth strategies

Maravai LifeSciences Holdings navigates Q1 2024 with solid revenue, strategic partnerships, and a focus on growth and innovation.
Despite debt challenges, the company's strong cash position, cost reduction efforts, and margin improvement targets signal resilience and adaptability.
Opportunities in GMP product growth, M&A activities, and customer journey insights position Maravai for continued success and market leadership.
Addressing challenges in debt management, cost optimization, and revenue forecasting will be key to sustaining growth and profitability.

Maravai LifeSciences maintains solid financials and strategic partnerships for growth

Maravai LifeSciences demonstrates financial stability and growth potential with steady revenue guidance.
Operational successes at Flanders facilities and new product offerings enhance market competitiveness.
Challenges in managing costs and maximizing profitability require strategic decision-making.
Strategic partnerships and focus on sustainability present opportunities for market expansion and innovation.

Maravai LifeSciences reports Q3 revenue, lowers 2024 guidance, eyes acquisitions

Maravai LifeSciences Holdings faced challenges in Q3 2024 but showcased strengths in its Nucleic Acid Production segment and strategic initiatives. The company is focused on growth opportunities in mRNA technologies and expanding its product portfolio through acquisitions and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of November.

Maravai LifeSciences Announces November 2023 Investor Conference Schedule

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Deb Hart - Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Executive Vice President and Chief Commercial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tom Peterson - Baird Matt Larew - William Blair Michael Ryskin - Bank of America Conor McNamara - RBC Capital Markets Dan Arias - Stifel Justin Bowers - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by. My name is Tammy and I will be your conference operator today.

Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2023 Earnings Call Transcript

SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2023 financial and operating results after the market closes on Tuesday, November 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai LifeSciences To Host Earnings Conference Call on Tuesday, November 7, 2023

Highlights include the company's strong foundation for growth, focus on innovation and attractive long-term outlook Highlights include the company's strong foundation for growth, focus on innovation and attractive long-term outlook

Maravai LifeSciences Hosts 2023 Investor R&D Day

SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Chief Innovation Officer Kate Broderick, PhD, has been named to the 2023 PharmaVoice 100 list, which recognizes the most inspiring leaders in the life sciences.

Maravai LifeSciences Chief Innovation Officer Kate Broderick Named to 2023 PharmaVoice 100

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it will host its 2023 Investor R&D Day on Thursday, September 28, starting at 10 a.m. ET in New York City.

Maravai LifeSciences to Host 2023 Investor R&D Day

LELAND, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Cygnus Technologies, part of Maravai LifeSciences (Maravai) (NASDAQ: MRVI), the leading product and services provider for the detection and characterization of process-related impurities in biopharmaceuticals, received a 2023 R&D 100 Award from R&D World Magazine in the Analytical/Test category for the MockV® RVLP Kit.

Cygnus Technologies Receives 2023 R&D 100 Award for MockV® RVLP Kit

SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of August.

Maravai LifeSciences Announces August 2023 Investor Conference Schedule

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2023 Earnings Call Transcript August 7, 2023 5:00 PM ET Company Participants Debra Hart - Head of IR Carl Hull - Executive Chairman of the Board Trey Martin - CEO Kevin Herde - CFO Becky Buzzeo - CCO Drew Burch - EVP, and GM Nucleic Acid Production Conference Call Participants Matt Sykes - Goldman Sachs Conor McNamara - RBC Capital Markets Dan Leonard - Credit Suisse Catherine Schulte - Baird Justin Bowers - Deutsche Bank Tejas Savant - Morgan Stanley Madeline Mollman - William Blair John Sourbeer - UBS Operator Thank you for standing by. I would like to welcome everyone to the Quarter Two 2023 Maravai LifeSciences' Earnings Conference Call.

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2023 Earnings Call Transcript

Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation

Maravai LifeSciences Reports Second Quarter 2023 Financial Results

GlobeNewswire window.initGradientEffect = function () { } document.addEventListener('DOMContentLoaded', function () { const extendedTableZoomElements = document.querySelectorAll('.extended-table-zoom'); if (extendedTableZoomElements && extendedTableZoomElements.length > 0) { window.Stickyfill.add(extendedTableZoomElements); } const socialMediaSideBarContainerElement = document.querySelectorAll('.social-media-side-bar-container'); if (socialMediaSideBarContainerElement && socialMediaSideBarContainerElement.length > 0) { window.Stickyfill.add(socialMediaSideBarContainerElement); } }, false); window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-ERWPGTJ5X8'); Accessibility: Skip TopNav // used in ui component window.pnrApplicationSettings = { Application:"pnr", SelectedLocale: 'en-US', PnrHostUrl: 'https://www.globenewswire.com', IsAuthenticated: false, ContextUser: '', ApplicationUrl: 'https://www.globenewswire.com', PageContext: '', SubscriptionId: 0, SubscriptionName: '', ArticleLogoUrl: '', ArticleHeadline: '', IsMobileVersion: 'False' === "True" ? true : false, HideLanguageSelection : false, NewsSearchHeading: '', ArticleMediaAttachments: [], AuthSessionExpirationMinutes: '0', AppLogoUrl: 'https://www.globenewswire.com/content/logo/color.svg', ReaderForgotPasswordUrl: 'https://pnrlogin.globenewswire.com/en/reset/confirmresetpassword', ReaderRegisterUrl: 'https://pnrlogin.globenewswire.com/en/register', IsQuickSignInEnabled: true, ReaderAccountBaseUrl: '' }; We're sorry, you encountered a page that doesn't exist.

Maravai LifeSciences Announces Completion of Planned CEO Leadership Transition

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2023 financial and operating results after the market closes on Monday, August 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai LifeSciences To Host Earnings Conference Call on Monday, August 7, 2023

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Robert (“Chip”) Hance has stepped down from the Company's Board of Directors (the “Board”) effective July 19, 2023, and that Dr. John DeFord has been appointed to the Board effective July 20, 2023.

Maravai LifeSciences Announces Appointment of New Director to the Board

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Deb Hart - Head of Investor Relations Carl Hull - Chairman of the Board and Interim CEO Kevin Herde - Chief Financial Officer Becky Buzzeo - Chief Commercial Officer Trey Martin - President Biologics Safety Testing Drew Burch - EVP, Nucleic Acid Production Conference Call Participants Conor McNamara - RBC Capital Markets Catherine Schulte - Robert W. Baird Matthew Sykes - Goldman Sachs Daniel Leonard - Credit Suisse Daniel Arias - Stifel John Sourbeer - UBS Tejas Savant - Morgan Stanley Operator Good afternoon.

Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2023 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (MRVI) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.54 per share a year ago.

Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue Estimates

SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2023 financial and operating results after the market closes on Monday, May 8, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai LifeSciences To Host Earnings Conference Call on Monday, May 8, 2023

- Highlights progress across five priority areas focused on building a foundation for sustainable growth.

Maravai LifeSciences Releases 2022 Environmental, Social and Governance (ESG) Report

Moderna

Long-term investments in biotech tend to be hard to come by. Moderna's gargantuan pipeline means that it has a very long growth runway ahead.

2 Top Biotech Stocks to Buy In March and Hold Forever

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of March.

Maravai LifeSciences Announces March 2023 Investor Conference Schedule

Inmode Ltd

There isn't much that's stopping them from penetrating their markets globally.

Don't Miss Out on These 2 Undervalued Stocks With Huge Growth Potential

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q4 2022 Earnings Conference Call February 22, 2023 5:00 PM ET Company Participants Debra Hart - Head of Investor Relations Carl Hull - Interim Chief Executive Officer Kevin Herde - Chief Financial Officer Trey Martin - President of Biologic Safety Testing Becky Buzzeo - Chief Commercial Officer Conference Call Participants Dan Leonard - Credit Suisse Matthew Sykes - Goldman Sachs Daniel Arias - Stifel Catherine Schulte - Robert W. Baird Tejas Savant - Morgan Stanley Operator Greetings, and welcome to the Fourth Quarter and Year-end 2022 Maravai LifeSciences Earnings Conference Call.

Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2022 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 2.94% and 0.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q4 Earnings Estimates

Base business revenues, excluding COVID-19 related CleanCap® revenues, were up 67% in the fourth quarter and up 17% for the full year

Maravai LifeSciences Reports Fourth Quarter and Full Year 2022 Financial Results

Maravai LifeSciences Holdings, Inc. (MRVI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Maravai LifeSciences Holdings, Inc. (MRVI) Q4 Earnings Expected to Decline

GoodRx Holdings

These stocks are also cheap buys that are down more than 60% from their highs.

News for Maravai LifeSciences Holdings Stock (MRVI)